{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:15:02Z","timestamp":1774894502146,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"DOI":"10.7759\/cureus.92735","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T18:56:52Z","timestamp":1758308212000},"source":"Crossref","is-referenced-by-count":1,"title":["Evidence-Based Management of Heart Failure: Clinical Impact and National Health Service Implications"],"prefix":"10.7759","author":[{"given":"Rudransh","family":"Guleria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardil  P","family":"Majmudar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi Yi","family":"Ang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Heart Failure Audit (NHFA). (2024). https.\/\/www.nicor.org.uk\/national-cardiac-audit-programme\/heart-failure-audit-nhfa."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad N","year":"2018","unstructured":"Conrad N, Judge A, Tran J, et al.. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018, 391:572-80. 10.1016\/S0140-6736(17)32520-5","journal-title":"Lancet"},{"key":"ref3","unstructured":"Cardiovascular diseases (CVDs). (2023). Accessed. 31st July 2023: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)."},{"key":"ref4","unstructured":"The NHS Long Term Plan - summary. (2019). https.\/\/www.transformationpartners.nhs.uk\/wp-content\/uploads\/2019\/01\/The-NHS-Long-Term-Plan-HLP-summary.pdf."},{"key":"ref5","unstructured":"Chronic heart failure in adults. diagnosis and management. (2023). https:\/\/www.nice.org.uk\/guidance\/ng106."},{"key":"ref6","unstructured":"UK cardiovascular disease factsheet. (2023). https.\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-cvd-statistics-uk-factsheet.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab670","article-title":"Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021, 42:4901. 10.1093\/eurheartj\/ehab670","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987, 316.1429-35. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg K","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010, 376:875-85. 10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref14","unstructured":"Cardiovascular disease. (2021). https.\/\/fingertips.phe.org.uk\/profile\/cardiovascular."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski P","year":"2014","unstructured":"Ponikowski P, Anker SD, AlHabib KF, et al.. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014, 1:4-25. 10.1002\/ehf2.12005","journal-title":"ESC Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety and efficacy of rapid optimisation of heart failure therapy: STRONG-HF trial","volume":"400","author":"Mebazaa A","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O. Safety and efficacy of rapid optimisation of heart failure therapy: STRONG-HF trial. Lancet. 2022, 400:1938-52. 10.1016\/S0140-6736(22)02076-1","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393788-evidence-based-management-of-heart-failure-clinical-impact-and-national-health-service-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T18:56:54Z","timestamp":1758308214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393788-evidence-based-management-of-heart-failure-clinical-impact-and-national-health-service-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.92735","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}